In this Q&A, Ping Liu, PhD, and Pietro Ravani, MD, PhD, answer our questions about the diagnosis and management of chronic kidney disease and discuss how the current definition of CKD does not consider age-related kidney function decline.
To evaluate the existing data on this issue, researchers developed a protocol to comprehensively identify all cohort studies that compared the risk of CKD in coffee drinkers with the risk in non-coffee-drinkers and to combine and analyze the results of these studies.
In this article, James Matera, DO, writes about the benefits of using SGLT2 inhibitors to treat patients with type 2 diabetes, chronic kidney disease, and cardiovascular disease, including how the use of SGLT2 inhibitors can help address racial and ethnic disparities in health care.
In FIGARO-DKD, the primary outcome measure is a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Of these outcomes, do you know the predominant outcome? Test your knowledge with our latest pop quiz!
New research sheds light on a novel biomarker that may accurately predict new-onset peripheral arterial disease in patients with mild to moderate chronic kidney disease. Researcher Scott E. Janus, MD, answers our questions.
According to the FIDELIO-DKD trial, do you know finerenone’s impact on incidence of the composite cardiovascular outcome? Test your knowledge with our latest pop quiz!
A 67-year-old man presented to the office for a general medical examination. He had no new or significant symptoms to report. Of particular interest, 16 years ago, abdominal ultrasonography for gastrointestinal tract reasons had shown an incidental 2.3-cm renal mass.
In a recent study, researchers investigated the effects of weight fluctuations in patients with chronic kidney disease on risk of cardiovascular-related outcomes and mortality.
James Matera, DO, discusses how lipid disorders impact the management of chronic kidney disease (CKD), and whether statins are safe for use in patients with comorbid lipid disorders and CKD.
In this podcast, Kim Zuber, PA-C, explains the current gold standard for monitoring and following patients with chronic kidney disease and what has been done to ensure standardized laboratory monitoring for early CKD. She also presented on this topic at the annual AAPA 2021 meeting.